Cargando…

Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Drug-Resistant Gastrointestinal Stromal Tumors: A Feasibility Study

BACKGROUND: As an emerging clinical problem, locally advanced drug-resistant gastrointestinal stromal tumors (LADRGISTs) has relatively few therapeutic schemes. Although radiotherapy is not often considered for GISTs, it could be a valuable contributing modality. The aim of our study is to explore a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Longhao, Yi, Xin, Cui, Haixia, Zhao, Xuemei, Dang, Jun, Jiang, Qingfeng, Li, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719822/
https://www.ncbi.nlm.nih.gov/pubmed/33330024
http://dx.doi.org/10.3389/fonc.2020.545892
_version_ 1783619758098219008
author Li, Longhao
Yi, Xin
Cui, Haixia
Zhao, Xuemei
Dang, Jun
Jiang, Qingfeng
Li, Ying
author_facet Li, Longhao
Yi, Xin
Cui, Haixia
Zhao, Xuemei
Dang, Jun
Jiang, Qingfeng
Li, Ying
author_sort Li, Longhao
collection PubMed
description BACKGROUND: As an emerging clinical problem, locally advanced drug-resistant gastrointestinal stromal tumors (LADRGISTs) has relatively few therapeutic schemes. Although radiotherapy is not often considered for GISTs, it could be a valuable contributing modality. The aim of our study is to explore a safe and effective radiation regimen for LADR-GISTs. METHODS: Three patients with LADR-GISTs were treated with simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) plans. In the SIB-IMRT plans, gross target volume (GTV) was divided into GTV-outer, GTV-mid, and GTV-center. And the prescribed dose of planning gross target volume (PGTV) and GTV-outer were both set to 50.4 Gy in 28 fractions. GTV-mid and GTV-center were simultaneously boosted to 60–62 Gy and 62–64 Gy respectively. For comparison purposes, conventional IMRT (Con-IMRT) plans with uniform dose distribution were generated for same optimization objectives without a dose boost to GTV-mid and GTV-center. All plans were optimized to make sure that deliver at least 95% of the prescription dose was delivered to PGTV. Isodose distribution, dose profiles, conformity indexes (CIs), monitor units (MUs), and dose volume histogram (DVH) was evaluated for each individual patient. After the three patients were treated with SIB-IMRT plans, the relative changes in the tumor size and CT values by CT scanning were also tracked. RESULTS: Compared with Con-IMRT plans, SIB-IMRT plans saw a significant increase from D(95) to D(2) of the GTV. With steeper dose gradients in the dose profiles, SIB-IMRT plans had GTV-mid and GTV-center accumulated with higher dose mainly by delivering extra 93 MUs in average. However, there was no significant difference in CIs and organs at risks (OARs) DVH. The relative changes in tumor size and CT values of the three patients in follow up were up to the Choi criteria and the three patients were all assessed as partial response. CONCLUSIONS: The proposed SIB-IMRT may be a potential technique for achieving objective response and prolonging survival of selected GISTs patients.
format Online
Article
Text
id pubmed-7719822
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77198222020-12-15 Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Drug-Resistant Gastrointestinal Stromal Tumors: A Feasibility Study Li, Longhao Yi, Xin Cui, Haixia Zhao, Xuemei Dang, Jun Jiang, Qingfeng Li, Ying Front Oncol Oncology BACKGROUND: As an emerging clinical problem, locally advanced drug-resistant gastrointestinal stromal tumors (LADRGISTs) has relatively few therapeutic schemes. Although radiotherapy is not often considered for GISTs, it could be a valuable contributing modality. The aim of our study is to explore a safe and effective radiation regimen for LADR-GISTs. METHODS: Three patients with LADR-GISTs were treated with simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) plans. In the SIB-IMRT plans, gross target volume (GTV) was divided into GTV-outer, GTV-mid, and GTV-center. And the prescribed dose of planning gross target volume (PGTV) and GTV-outer were both set to 50.4 Gy in 28 fractions. GTV-mid and GTV-center were simultaneously boosted to 60–62 Gy and 62–64 Gy respectively. For comparison purposes, conventional IMRT (Con-IMRT) plans with uniform dose distribution were generated for same optimization objectives without a dose boost to GTV-mid and GTV-center. All plans were optimized to make sure that deliver at least 95% of the prescription dose was delivered to PGTV. Isodose distribution, dose profiles, conformity indexes (CIs), monitor units (MUs), and dose volume histogram (DVH) was evaluated for each individual patient. After the three patients were treated with SIB-IMRT plans, the relative changes in the tumor size and CT values by CT scanning were also tracked. RESULTS: Compared with Con-IMRT plans, SIB-IMRT plans saw a significant increase from D(95) to D(2) of the GTV. With steeper dose gradients in the dose profiles, SIB-IMRT plans had GTV-mid and GTV-center accumulated with higher dose mainly by delivering extra 93 MUs in average. However, there was no significant difference in CIs and organs at risks (OARs) DVH. The relative changes in tumor size and CT values of the three patients in follow up were up to the Choi criteria and the three patients were all assessed as partial response. CONCLUSIONS: The proposed SIB-IMRT may be a potential technique for achieving objective response and prolonging survival of selected GISTs patients. Frontiers Media S.A. 2020-11-23 /pmc/articles/PMC7719822/ /pubmed/33330024 http://dx.doi.org/10.3389/fonc.2020.545892 Text en Copyright © 2020 Li, Yi, Cui, Zhao, Dang, Jiang and Li http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Longhao
Yi, Xin
Cui, Haixia
Zhao, Xuemei
Dang, Jun
Jiang, Qingfeng
Li, Ying
Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Drug-Resistant Gastrointestinal Stromal Tumors: A Feasibility Study
title Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Drug-Resistant Gastrointestinal Stromal Tumors: A Feasibility Study
title_full Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Drug-Resistant Gastrointestinal Stromal Tumors: A Feasibility Study
title_fullStr Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Drug-Resistant Gastrointestinal Stromal Tumors: A Feasibility Study
title_full_unstemmed Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Drug-Resistant Gastrointestinal Stromal Tumors: A Feasibility Study
title_short Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Drug-Resistant Gastrointestinal Stromal Tumors: A Feasibility Study
title_sort simultaneous integrated boost intensity-modulated radiotherapy for locally advanced drug-resistant gastrointestinal stromal tumors: a feasibility study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719822/
https://www.ncbi.nlm.nih.gov/pubmed/33330024
http://dx.doi.org/10.3389/fonc.2020.545892
work_keys_str_mv AT lilonghao simultaneousintegratedboostintensitymodulatedradiotherapyforlocallyadvanceddrugresistantgastrointestinalstromaltumorsafeasibilitystudy
AT yixin simultaneousintegratedboostintensitymodulatedradiotherapyforlocallyadvanceddrugresistantgastrointestinalstromaltumorsafeasibilitystudy
AT cuihaixia simultaneousintegratedboostintensitymodulatedradiotherapyforlocallyadvanceddrugresistantgastrointestinalstromaltumorsafeasibilitystudy
AT zhaoxuemei simultaneousintegratedboostintensitymodulatedradiotherapyforlocallyadvanceddrugresistantgastrointestinalstromaltumorsafeasibilitystudy
AT dangjun simultaneousintegratedboostintensitymodulatedradiotherapyforlocallyadvanceddrugresistantgastrointestinalstromaltumorsafeasibilitystudy
AT jiangqingfeng simultaneousintegratedboostintensitymodulatedradiotherapyforlocallyadvanceddrugresistantgastrointestinalstromaltumorsafeasibilitystudy
AT liying simultaneousintegratedboostintensitymodulatedradiotherapyforlocallyadvanceddrugresistantgastrointestinalstromaltumorsafeasibilitystudy